Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quentiv
- Development stage
- Phase 3
- Lead developer
- KM Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
KD-370 (Quentiv) is a pentavalent combination vaccine developed by KM Biologics (a subsidiary of Meiji Holdings, which acquired the vaccine business of The Chemo-Sero-Therapeutic Research Institute, or Kaketsuken). It is designed for the active immunization of infants and children against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive infections caused by Haemophilus influenzae type b (Hib). The vaccine formulation combines diphtheria and tetanus toxoids, acellular pertussis components (including pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae), Sabin-strain inactivated poliovirus (sIPV) types 1, 2, and 3, and Hib capsular polysaccharide conjugated to a tetanus toxoid carrier protein. Administered via subcutaneous injection, KD-370 was approved in Japan in March 2023, simplifying the pediatric immunization schedule by reducing the number of required injections compared to separate quadrivalent and Hib vaccinations.
- Brand names
- Quentiv
- Other names
- DTaP-sIPV-Hib vaccinepentavalent vaccine5-in-1 vaccineKD370KD-370KD 370
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Fim2 (Bordetella pertussis fimbrial protein 2)Fimbrial antigen type 3CD4+ T-cell receptor recognizing poliovirus capsid-derived peptidesPV-TCR (Poliovirus capsid-specific CD8+ T-cell receptor)PRR (Pattern recognition receptors)PV-D-BCR (Naïve B-cell receptor specific for poliovirus D-antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Quentiv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quentiv.